The use of cannabinoids in MS: is it evidence based?                      (abst – undated)                        


Marihuana as a therapeutic agent for muscle spasm or spasticity                      (abst – 1980)


Tetrahydrocannabinol for tremor in multiple sclerosis.                      (abst – 1983)


Delta-9-THC in the treatment of spasticity associated with retinopathy.                    (abst – 1987)


Effect of cannabinoids on spasticity and ataxia in multiple sclerosis.                   (abst – 1989)


Nabilone in the treatment of multiple sclerosis                     (abst – 1995)


The effect of orally and rectally administered delta-9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients.                                                      (abst – 1996)


The perceived effects of smoked cannabis on patients with multiple sclerosis. (abst – 1997)


Cannabis and cannabinoids: pharmacology and rationale for clinical use                      (abst – 1999)


Analgesic effect of the cannabinoid analogue nabilone is not mediated by opioid receptors.          (abst – 1999)


Endocannabinoids control spasticity in a multiple sclerosis model                      (full – 2000)  0399fjev1?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=cannabis&andorexactfulltext=and&sear  chid=1&FIRSTINDEX=10&sortspec=relevance&resourcetype=HWCIT










Cannabinoids might reduce spasticity in multiple sclerosis                 (full – 2000)


Cannabinoids control spasticity and tremor in a multiple sclerosis model                 (full – 2000)


Cannabinoids reduce tremor in animal model of multiple sclerosis               (news – 2000)  http://www.cannabis-,reduce,tre mor,in,animal,model,of,multiple,sclerosis#2


Therapeutic aspects of cannabis and cannabinoids.               (full – 2001)


Acute and chronic effects of cannabis based medicinal extract on refractory lower urinary tract dysfunction in patients with advanced multiple sclerosis – early results

(abst – 2001)


The cannabinoids: an overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection. (abst – 2001)                            


Chronic Cannabis Use in the Compassionate Investigational New Drug Program: An Examination of Benefits and Adverse Effects of Legal Clinical Cannabis (full – 2002)


Cannabinoids in the treatment of pain and spasticity in multiple sclerosis. (abst – 2002) tplus


Cannabinoids and multiple sclerosis.              (abst – 2002)


Marijuana Helps MS Patients Alleviate Pain, Spasms               (news – 2002)



(news – 2002)  WALK.-a082609025


Cannabis Use As Described by People with Multiple Sclerosis.              (full – 2003)


Therapeutic Action of Cannabinoids in a Murine Model of Multiple Sclerosis (full – 2003)






=cannabis&andorexactfulltext=and&searchid=1&FIRSTINDEX=20&sortspec=relevance&resourcetype=H  WCIT


Cannabinoids inhibit neurodegeneration in models of multiple sclerosis                (full – 2003)  2989ba0


Whether whole plant Cannabis extracts can improve intractable neurogenic symptoms? (full – 2003)                         


Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R(+)WIN55,212           (full – 2003)


Cannabinoids inhibit neurodegeneration in models of multiple sclerosis                (full – 2003)


Randomised controlled trial of cannabis based medicinal extracts (CBME) in central neuropathic pain due to multiple sclerosis.                                                       (abst – 2003)


Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial.                                         (abst – 2003)


Therapeutic potential of cannabinoids in CNS disease.                (abst – 2003)


‘How cannabis helped me’                (news/anecdotal – 2003)


Cannabis helps symptoms of multiple sclerosis: study               (news – 2003)


Cannabis May Help Multiple Sclerosis               (news – 2003)


Cannabis can help MS sufferers                (news – 2003)  (may need registration)


Initial experiences with medicinal extracts of cannabis for chronic pain: Results from 34 ‘N of 1’ studies            (full – 2004)                


Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial                                                 (full – 2004)


Cannabinoids and neuroinflammation               (full – 2004)







Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients.         (full – 2004)


Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study.  (full – 2004)


An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis.      (full – 2004)


Multiple Sclerosis Following Treatment with a Cannabinoid Receptor-1 Antagonist. (abst – 2004)                         


Are oral cannabinoids safe and effective in refractory neuropathic pain?             (abst – 2004)


Cannabis study encouraging for MS               (news – 2004)


Cannabis Relieves Multiple Sclerosis Pain                (news – 2004)


Cannabis truly helps multiple sclerosis sufferers               (news – 2004) (may need registration)


Therapy Insight: Bladder Dysfunction Associated With Multiple Sclerosis             (full – 2005)


Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation (full – 2005)                       


Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up       (full – 2005)


Emerging properties of cannabinoid medicines in the management of multiple sclerosis (full – 2005)                         


The synthetic cannabinoid R(+)WIN 55,212-2 inhibits the interleukin-1 signaling pathway in human astrocytes in a cannabinoid receptor-independent manner. (full – 2005)










Sativex: Fact Sheet             (full – 2005)


Sativex: Health Care Professional letter              (letter – 2005)


Cannabinoids in multiple sclerosis — therapeutically reasonable?               (abst – 2005)


Cannabinoid control of motor function at the basal ganglia.              (abst – 2005)


Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis.

(abst – 2005)      


Cannabis-based medicine in central pain in multiple sclerosis               (abst – 2005)


Cannabinoids and neuroprotection in CNS inflammatory disease.           (abst – 2005)


Therapeutic action of cannabinoid on axonal injury induced by peroxynitrite (abst – 2005)                          


Cannabis-based medicinal extract (Sativex) produced significant improvements in a subjective measure of spasticity which were maintained on long-term treatment with no evidence of tolerance.       (abst – 2005)


Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis.       (abst – 2005)


Marijuana derivatives may provide MS treatment               (news – 2005)


Medicinal marijuana use Experiences of people with multiple sclerosis

(full – 2006)   


Experimental autoimmune encephalomyelitis disrupts endocannabinoid-mediated neuroprotection          (full – 2006)


Role of the Cannabinoid System in Pain Control and Therapeutic Implications for the Management of Acute and Chronic Pain Episodes                                                           (full – 2006)









Multiple sclerosis may disrupt endocannabinoid brain protection mechanism

(full – 2006)          


Cannabinoids In Medicine: A Review Of Their Therapeutic Potential                  (full – 2006)


US Patent Application 20060167084 – Delta-9-THC compositions and methods for treating symptoms associated with multiple sclerosis                                                                (full – 2006 )


Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis.                                                                    (abst – 2006)


UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington’s disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders.                                                                                           (abst – 2006)


Sativex in patients with symptoms of spasticity due to multiple sclerosis

(abst – 2006)     


Randomised controlled study of cannabis-based medicine (Sativex®) in patients suffering from multiple sclerosis associated detrusor overactivity                                                                   (abst – 2006)


The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS).                                                                   (abst – 2006)


Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain : A double-blind placebo-controlled cross-over trial.

(abst – 2006)      


Cuppa Gives A Better ‘ooh’             (news – 2006)


The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis                                     (full – 2007)


Cannabinoid control of neuroinflammation related to multiple sclerosis

(full – 2007)   


CB2 cannabinoid receptors as an emerging target for demyelinating diseases: from neuroimmune interactions to cell replacement strategies                                                                     (full – 2007)









Cannabinoid CB1 and CB2 Receptors and Fatty Acid Amide Hydrolase Are Specific Markers of Plaque Cell Subtypes in Human Multiple Sclerosis                                                      (full – 2007)




The endocannabinoid system in targeting inflammatory neurodegenerative diseases (full – 2007) ry_neuro.pdf


Control of Spasticity in a Multiple Sclerosis Model is mediated by CB1, not CB2, Cannabinoid Receptors          (full – 2007)


Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis           (full – 2007)


Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain.   (abst – 2007)            


Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.

(abst – 2007)          


The endocannabinoid system and neurogenesis in health and disease.               (abst – 2007)


The (Endo)Cannabinoid System in Multiple Sclerosis and Amyotrophic Lateral Sclerosis (abst – 2007)                          


Cannabinoids and neuroprotection in motor-related disorders.            (abst – 2007)


Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption                                          (abst – 2007)


Cannabis-based medicine in spasticity caused by multiple sclerosis.               (abst – 2007)  f_cannabis_based_medicine_in_spasticity_caused_by_multiple_sclerosis


Excitotoxicity in a chronic model of multiple sclerosis: Neuroprotective effects of cannabinoids through CB1 and CB2 receptor activation.                                                                 (abst – 2007)


Cannabis based treatments for neuropathic and multiple sclerosis-related pain. (abst – 2007)







Symptomatic treatment of multiple sclerosis using cannabinoids: recent advances. (abst – 2007)                          


Cannabis’ Potential Exciting Researchers in Treatment of ALS, Parkinson’s Disease (news – 2007)                           


Cannabis could hold the key to ending multiple sclerosis misery               (news – 2007)


Multiple sclerosis, cannabinoids, and cognition.               (full – 2008)


Cannabinoids in the management of difficult to treat pain              (full – 2008)


CB2 cannabinoid receptors as an emerging target for demyelinating diseases: from neuroimmune interactions to cell replacement strategies                                                                       (full – 2008)


The CB2 Cannabinoid Receptor Controls Myeloid Progenitor Trafficking INVOLVEMENT IN THE PATHOGENESIS OF AN ANIMAL MODEL OF

MULTIPLE SCLEROSIS              (full – 2008)


Cannabinoid CB2 receptors in human brain inflammation                  (full – 2008)


Cannabinoids in the management of spasticity associated with multiple sclerosis (full – 2008)                         


Current Status of Cannabis Treatment of Multiple Sclerosis with an Illustrative Case Presentation of a Patient with MS, Complex Vocal Tics, Paroxysmal Dystonia, and Marijuana Dependence Treated with Dronabinol.   (full – 2008)


The CB(2) cannabinoid receptor controls myeloid progenitor trafficking: involvement in the pathogenesis of an animal model of multiple sclerosis.                                                     (full – 2008)


US Patent Application 20080181942 – Delta-9-THC compositions and methods for treating symptoms associated with multiple sclerosis                                                                 (full – 2008)


The endocannabinoid system and multiple sclerosis.                (abst – 2008)









Abnormalities in the cerebrospinal fluid levels of endocannabinoids in multiple sclerosis. (abst – 2008)                             


Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis                                            (abst – 2008)


Cannabis use in Spanish patients with multiple sclerosis                (abst – 2008)  bmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum


Use Of Non-Psychoactive Cannabinoids In The Treatment Of Neurodegenerative Diseases.        (news – 2008)                  


Cannabis May Halt Progression Of Multiple Sclerosis              (news – 2008)


Can Cannabis Compounds Slow The Progression Of Multiple Sclerosis?             (news – 2008)


Emerging Role of the CB2 Cannabinoid Receptor in Immune Regulation and Therapeutic Prospects       (full – 2009)


Cannabinoids as Therapeutic Agents for Ablating Neuroinflammatory Disease (full – 2009)                        


Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review.      (full – 2009)


Cannabinoids as novel anti-inflammatory drugs.               (full – 2009)


Cannabidiol: a promising drug for neurodegenerative disorders?               (full – 2009)


The Endocannabinoid Anandamide: From Immunomodulation to Neuroprotection. Implications for Multiple Sclerosis                                                        (abst – 2009)


A review of complementary and alternative medicine (CAM) by people with multiple sclerosis.   (abst – 2009)




Plasma endocannabinoid levels in multiple sclerosis.                (abst – 2009)









Do cannabinoids reduce multiple sclerosis-related spasticity?                (abst – 2009) multiple_sclerosis_related_spasticity


Cannabinoids and neurodegenerative diseases.               (abst – 2009)


Medical Marijuana and Multiple Sclerosis (MS)                 (news – 2009)


Clinical phase III study with the cannabis extract Cannador successful in multiple sclerosis          (news – 2009)


Marijuana Eases Spasticity in MS Patients                (news – 2009)


Pot shows promise for reducing multiple sclerosis patients’ symptoms              (news – 2009)


Study Confirms That Cannabis Is Beneficial for Multiple Sclerosis             (news – 2009)


Marijuana Chemicals Ease MS Symptoms, Review Confirms               (news – 2009)


14 of 15 MS patients show clinical improvement with cannabis consumption (news – 2009) cannabis-consumption


Cannabis can reduce spasticity in MS patients              (news – 2009)


Standardized Cannabis in Multiple Sclerosis: A Case Report              (full – 2010)


New approaches in the management of spasticity in multiple sclerosis patients: role of cannabinoids        (full – 2010)


Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression. (full – 2010)                          


Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. (abst – 2010)                           


Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis                                                   (abst – 2010)







The endocannabinoid system in the inflammatory and neurodegenerative processes of multiple sclerosis and of amyotrophic lateral sclerosis.                                                          (abst – 2010)


The Multiplicity of Action of Cannabinoids: Implications for Treating Neurodegeneration.           (abst – 2010)                                   


Julie Falco brings hope to Multiple Sclerosis patients. Cannabinoids manage pain and promote repair!      (news – 2010)  to-Multiple-Sclerosis-patients-Cannabinoids-manage-pain-and-promote-repair


Nature’s (Legal) Cannabinoids               (news – 2010)


Marijuana and MS–an unfinished story.               (news – 2010)–an+unfinished+story.-a0237205183


Weed Control Part 1: MS sufferer finds relief with medical marijuana (anecdotal/news – 2010)  marijuana/


Anandamide inhibits Theiler’s virus induced VCAM-1 in brain endothelial cells and reduces leukocyte transmigration in a model of blood brain barrier by activation of CB1 receptors.    (full – 2011)




Gadolinium-HU-308-incorporated micelles.                (full – 2011)


Is lipid signaling through cannabinoid 2 receptors part of a protective system? (full – 2011)                        


Emerging treatment options for spasticity in multiple sclerosis; clinical utility of cannabinoids      (link to PDF – 2011) ll&recNo=30&uiLanguage=en









Acute and chronic cannabinoid extracts administration affects motor function in a CREAE model of multiple sclerosis.                                                            (abst – 2011)


Role of cannabinoids in multiple sclerosis              (abst – 2011)


Inhibitory Effect of Standardized Cannabis sativa Extract and Its Ingredient Cannabidiol on Rat and Human Bladder Contractility.                                             (abst – 2011)


Identification of the synthetic cannabinoid R(+)WIN55,212-2 as a novel regulator of IFN regulatory factor 3 (IRF3) activation and IFN-{beta} expression: relevance to therapeutic effects in models of multiple sclerosis.                                                                            (abst – 2011)








A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis.     (abst – 2011)


Treating pain in multiple sclerosis.                (abst – 2011)


THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis.                                                   (abst – 2011)




New metabolic pathway for controlling brain inflammation                 (news – 2011)  inflammation.aspx


The synthetic cannabinoid R(+)WIN55,212-2 augments interferon-β expression via peroxisome proliferator-activated receptor-α                                                       (full – 2012)


Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial.          (full – 2012)               


Cannabinoid modulation of neuroinflammatory disorders.             (full – 2012)


Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB(1) receptor-mediated anti-inflammatory effects. (abst – 2012)









The synthetic cannabinoid R(+)WIN55,212-2 augments interferon-β expression via peroxisome proliferator-activated receptor-α                                                       (abst – 2012)


Cannabinoid receptor 2 agonists inhibit migration of activated dendritic cells via modulation of MMP-9 (abst – 2012)

=25&RESULTFORMAT=&fulltext=cannabinoid&searchid=1&FIRSTINDEX=130&sortspec=date&resou  rcetype=HWCIT


A questionnaire survey of patients and carers of patients prescribed Sativex as an unlicensed medicine.   (abst – 2012)                              


Potential Control of Multiple Sclerosis by Cannabis and the Endocannabinoid System. (abst – 2012)                             


Evaluation of the safety and tolerability profile of Sativex: is it reassuring enough? (abst – 2012)                          


Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity.                                                            (abst – 2012)


Multiple Sclerosis and Extract of Cannabis: results of the MUSEC trial.              (abst – 2012)


Evaluation of the Effects of Sativex (THC BDS: CBD BDS) on Inhibition of Spasticity in a Chronic Relapsing Experimental Allergic Autoimmune Encephalomyelitis: A Model of Multiple Sclerosis.    (abst – 2012)







Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis.     (abst – 2012)                    


Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity. (abst – 2012)                          


A Cannabigerol Quinone Alleviates Neuroinflammation in a Chronic Model of Multiple Sclerosis.          (abst – 2012)            


The therapeutic potential of cannabis and cannabinoids.              (abst – 2012)


Treatment of spasticity in multiple sclerosis: new perspectives regarding the use of cannabinoids  (abst – 2012)                             









Cost Effectiveness of Oromucosal Cannabis-Based Medicine (Sativex®) for Spasticity in Multiple Sclerosis.                                                     (abst – 2012)


Treatment of spasticity in multiple sclerosis: new perspectives regarding the use of cannabinoids  (abst – 2012)                               


CD200-CD200R1 interaction contributes to neuroprotective effects of anandamide on experimentally induced inflammation                                                               (abst – 2012)


What place for cannabis extract in MS?                     (abst – 2012)


A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis.                                                                                                      (abst – 2012)


Smoked Cannabis Reduces Some Symptoms of Multiple Sclerosis                    (news – 2012)  sclerosis.aspx


Endocannabinoid system modulator use in everyday clinical practice in the UK and Spain.          (abst – 2013)                      


Multiple sclerosis and the blood-central nervous system barrier.                      (abst – 2013)

Share a link for